SNTI
Senti BiosciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SNTI Profile
Senti Biosciences, Inc.
A biotech company that innovating cell and gene therapies using its proprietary gene circuit platform
2 Corporate Drive, First Floor, South San Francisco, CA 94080
--
Senti Biosciences, Inc., was incorporated in Delaware on March 1, 2021. The company is a preclinical biotechnology company that develops next-generation cell and gene therapies designed with its gene circuit platform technology to combat challenging diseases. The company's mission is to create a new generation of smarter therapies to defeat complex diseases in a way that traditional medicines cannot. To accomplish this mission, Senti Biosciences has built a synthetic biology platform that it believes may enable it to program the next generation of cells and gene therapies with so-called "gene circuits. ". Created by Senti Biosciences with novel and proprietary combinations of gene parts, these gene circuits are designed to reprogram cells with biological logic to sense inputs, computational decisions, and respond to their respective cellular environments. Senti Biosciences gene circuit platform technology can be applied in a pattern-independent manner for natural killer cells, T cells, tumor-infiltrating lymphocytes, stem cells including hematopoietic stem cells, in vivo gene therapy and messenger ribonucleic acid.
